Citi Sticks to Its Buy Rating for BNP Paribas (0HB5)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Coombs covers the Financial sector, focusing on stocks such as UBS Group AG, Deutsche Bank AG, and Barclays. According to TipRanks, Coombs has an average return of 17.7% and a 74.04% success rate on recommended stocks.
In addition to Citi, BNP Paribas also received a Buy from Goldman Sachs's Chris Hallam in a report issued on July 11. However, on July 10, J.P. Morgan maintained a Hold rating on BNP Paribas (LSE: 0HB5).
Based on BNP Paribas' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €29.52 billion and a net profit of €2.32 billion. In comparison, last year the company earned a revenue of €24.63 billion and had a net profit of €1.07 billion
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
QQQ ETF News, 8/7/2025
How is QQQ stock faring? The Invesco QQQ ETF has risen 1.83% over the past five days and is up 9.88% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, QQQ is a Moderate Buy. The Street's average price target of $624.63 for the QQQ ETF implies an upside of 10.1%. Currently, QQQ's five holdings with the highest upside potential are Charter Communications (CHTR), Strategy (MSTR), Atlassian Corporation (TEAM), Lululemon Athletica (LULU), and Adobe Systems (ADBE). Meanwhile, its five holdings with the greatest downside potential are Shopify (SHOP), Palantir Technologies (PLTR), Fastenal (FAST), Tesla Motors (TSLA), and Constellation Energy (CEG). Power up your ETF investing with TipRanks. Discover the ETFs with High Upside Potential, carefully curated based on TipRanks' analysis.
Business Insider
3 hours ago
- Business Insider
Google to commit $1B to support AI education, job training, research
In a blog post, Google wrote, 'Millions of college students around the world are getting ready to start classes. To help make the school year even better, we're making our most advanced AI tools available to them for free, including our new Guided Learning mode. We're also providing $1 billion to support AI education and job training programs and research in the U.S. This includes making our AI and career training free for every college student in America through our AI for Education Accelerator – over 100 colleges and universities have already signed up.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yahoo
3 hours ago
- Yahoo
Eli Lilly's Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, Eli Lilly announced the topline results from its SURPASS-CVOT trial/NCT04255433, which is a phase III study that investigated the cardiovascular benefits of its dual-agonist drug Mounjaro (tirzepatide). The ~5-year trial involved 13,299 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, comparing once-weekly Mounjaro against Trulicity (dulaglutide), which is another GLP-1 RA from Eli Lilly. The study achieved its primary endpoint by demonstrating Mounjaro's noninferiority to Trulicity in reducing the 3 major adverse cardiovascular events/MACE-3, which include cardiovascular death, heart attack, or stroke. Overall, Mounjaro reduced the MACE-3 by 8% compared to Trulicity. Analysts from William Blair and Citi expressed disappointment that the trial did not show superiority over Trulicity. A close-up of a staff member counting pills in a pharmaceutical warehouse. Mounjaro reduced MACE-3 by an estimated 28% and all-cause mortality by 39% when compared to a placebo. Additionally, Mounjaro led to greater improvements in A1C, weight, and cardiovascular biomarkers. A significant finding was a 16% lower rate of all-cause mortality compared to Trulicity, as well as greater kidney protection Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
